The Reduction and Association of the Scaphoid and Lunate (RASL) system, which Acumed purchased for an undisclosed amount, has 510(k) clearance from the FDA.
Roughly 120,000 people in the U.S. are affected by chronic injury to the scapholunate ligament each year, according to Acumed. The RASL system will add to the company’s existing hand and wrist portfolio, which also includes wrist plating options and the Acutrak 2 Headless Compression Screw.
“This acquisition will further strengthen Acumed’s position to deliver compelling and comprehensive solutions to address fractures and associated soft tissue injuries of the hand and wrist,” Acumed president & CEO Sharon Wolfington said in prepared remarks.
“Acumed will continue to build its portfolio to meet the unmet needs of the fellowship-trained hand and upper extremity, sports medicine, foot and ankle, and trauma surgeons. We will do this both with organic innovation and with acceleration acquisitions,” Jagi Gill, VP/GM of Acumed subsidiary AcuVentures, added.